AstraZeneca PLCAZN:LSE

4,473.5
48.50 / 1.10%
1.92m
4.64%
0.3792
Close in GBXToday's changeShares traded1 year changeBeta
Data delayed at least 15 minutes, as of May 22 2015 17:07 BST.

About the company

16.62bn825.80m199257.50k
Revenue in GBP (TTM)Net income in GBPIncorporatedEmployees
IndustryPharmaceuticals & BiotechnologyLocation
AstraZeneca PLC
- Legal Department, 2 Kingdom Street
LONDONW2 6BD
United Kingdom
GBR
Phone+44 20 7304 5000Fax+44 20 7604 8151Websitehttp://www.astrazeneca.com/
AstraZeneca PLC is the United Kingdom-based global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. It has a range of medicines that includes treatments for illnesses, such as its antibiotic, Merrem/Meronem and Losec/Prilosec for acid related diseases. AstraZeneca’s products include Crestor, Atacand,Seloken/Toprol-XL, Plendil, Onglyza, Zestril, Symbicort and Zoladex. The Company owns and operates a range of research and development (R&D), production and marketing facilities across the world. AstraZeneca operates in over 100 countries, including China, Mexico, Brazil and Russia.

Mergers & acquisitions

There are no recent mergers or acquisitions for AstraZeneca PLC.
Data delayed at least 15 minutes, as of May 22 2015 17:07 BST.

Peer analysis

Company Revenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings
(TTM)
Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excluding
extraordinary items (TTM)
EPS (including
extraordinary items) (TTM)
Revenue per
share (TTM)
Book value per
share (MRQ)
Asset turnover
(TTM)
Inventory turnover
(TTM)
Receivables turnover
(TTM)
Revenues per
employee (TTM)
Return on
average
assets
(TTM)
Return on
average
assets
(5 yr average)
Return on
investment
(TTM)
Return on
investment
(5 yr average)
Gross margin (TTM)Gross margin (5 yr average)Net profit margin (TTM)Net Profit margin (5 Yr Average)Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio (5 yr average)Revenue
(Year-over-year change%)
Revenue
(5 yr growth rate)
Net income
(Year-over-year change%)
Net income
(5 Yr growth rate)
Capital
expenditure
(5 Yr growth rate)
Dividend
(5 yr growth rate)
Shire PLC
3.89bn2.12bn33.14bn5.02k15.585.8914.118.523.593.736.599.500.54861.786.03775,16529.8825.5238.3125.5285.2485.8454.4729.931.53371.480.08947.3222.0514.90131.2545.47-21.686415.00
AstraZeneca plc
16.62bn825.80m57.15bn57.50k69.285.2218.833.440.65280.652813.158.660.45512.663.37288,9862.2714.463.2114.4678.6480.644.9819.170.68055.170.38464.411.49-4.473-51.7606-30.347411.654.01
GlaxoSmithKline plc
23.02bn10.18bn71.27bn98.70k6.949.596.613.102.112.114.751.530.47111.664.26233,17720.7814.9431.0114.9468.6771.2344.1015.481.038.220.618193.67-13.2013-4.1036-49.301-13.0048-1.3385.57
Sanofi SA
24.89bn3.07bn86.09bn113.50k28.48--17.443.463.243.2426.47--------309,033--5.57--5.5767.7969.0312.9213.15--14.59--73.022.411.7818.14-3.5698-3.13713.50
Novo Nordisk A/S
8.92bn2.85bn76.19bn39.06k34.0631.3424.008.5411.3911.3935.6512.381.331.337.452,286,86242.5047.6982.6947.6984.0282.3131.9227.710.742418.630.018245.826.2611.705.1519.727.1827.23
Data as of May 25 2015. Currency figures normalised to AstraZeneca PLC's reporting currency: .
Data delayed at least 20 minutes, as of May 25 2015 07:53 BST.

Institutional shareholders

HolderShares% Held
BlackRock Investment Management (UK) Ltd.
as of 31 Jan 2015
65.63m5.19%
Legal & General Investment Management Ltd.
as of 01 Apr 2015
38.00m3.01%
Wellington Management Co. LLP
as of 01 Apr 2015
33.92m2.69%
Norges Bank Investment Management
as of 01 Apr 2015
30.33m2.40%
Capital Research & Management Co. (World Investors)
as of 11 May 2015
28.93m2.29%
Invesco Asset Management Ltd.
as of 01 Apr 2015
25.54m2.02%
The Vanguard Group, Inc.
as of 01 Apr 2015
22.83m1.81%
Aberdeen Asset Investments Ltd.
as of 01 Apr 2015
19.51m1.54%
State Administration of Foreign Exchange (Invt Mgmt)
as of 01 Apr 2015
18.78m1.49%
Threadneedle Asset Management Ltd.
as of 01 Apr 2015
18.67m1.48%
23.91%
Per cent of shares
held by top holders
Data from 31 Dec 2014 - 21 May 2015Source: FactSet Research Systems Inc.
© Thomson Reuters Click for restrictions.

All markets data located on FT.com is subject to the FT Terms & Conditions.

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.